anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE: A composition for prevention and treatment of dementia containing an extract of Ganoderma lucidum(Fr.) Karst., oleamide and its structural analogue is provided. It exhibits prophylactic and therapeutic effect on vascular dementia as well as Alzheimer's disease. CONSTITUTION: The food composition for prevention and treatment of dementia contains a Ganoderma lucidum extract containing one or more effective fractions selected from GL-M, GL-M-8, GL-M-8-F-b, GL-M-8-F-b-III, GL-M-8-F-III-1. The food composition contains a compound represented by the formulae(1, 2 and 3) as an effective ingredient, wherein R1 is 9-octadecenoyl(oleyl), 9-hexadecenoly(palmitoleyl) or tetradecanoyl(myristyl). The composition inhibits the activity of acetylcholinesterase of the animal brain tissue and protecting effect on the brain tissue damaged by brain ischemia while preventing the reduction acetylcholine amount in the brain.
<P>PROBLEM TO BE SOLVED: To provide a composition for a delivery system of agents affecting required cells or areas and a method.  <P>SOLUTION: The problems of the subject are solved with the composition for the delivery system of the agents (including therapeutic compounds, pharmaceutical agents, drugs, detection agents, nucleic acid sequences and biological factors) and the method. The vector composition comprises a colloidal metal, a derivatized PEG and an agent. The invention comprises also methods for producing these colloidal metal compositions and for treating cancer and a composition. The vector composition is particularly effective in detecting or treating solid tumors. The suitable composition preferably contains colloidal metal sol, preferably, metal sol of gold combined with the derivatized PEG, preferably a thiol-PEG and possibly contains at least one agent which aids the vector to become a specific target, has a therapeutic effect or is detectable.  <P>COPYRIGHT: (C)2009,JPO&INPIT
PROBLEM TO BE SOLVED: To obtain a medicament useful in treating respiratory diseases including acute respiratory distress syndrome involving vasopermeability acceleration brought about due to various factors by including therapeutically effective amounts of active ingredient(s) for maintaining the activity or inhibiting the deactivation of a pulmonary surfactant. SOLUTION: This medicament is obtained by including therapeutically effective amounts of active ingredient(s) for maintaining the activity or inhibiting the deactivation of a pulmonary surfactant such as Surfactant CK and, pref. furthermore combining the active ingredient(s) with a pulmonary surfactant; wherein the active ingredient(s) is pref. at least one kind selected from saccharides (pref. polysaccharides such as dextran), derivatives thereof (pref. mannitol or the like) and pharmaceutically acceptable nontoxic salts thereof. It is preferable that the daily dose of this medicament is normally 10-50 g/adult for the active ingredient(s) singly through intravenous injection, while being 0.5-5 g for combining the active ingredient(s) with a pulmonary surfactant through intravenous injection or sinopulmonary administration.
Restless Legs Syndrome (RLS) is a chronic neurologic disease that causes painful and distressing dysesthesias in the lower extremities at night affecting sleep quality and greatly influencing general overall health. Leading theories as to the cause of RLS symptoms point to a deficiency of central nervous system dopamine levels. Cranial Electrical Stimulation (CES) is a therapy that has been shown to affect activity in dopaminergic regions of the brain. The purpose of this study is to assess the feasibility and efficacy of CES therapy in the management of symptoms of RLS. The overall study design will use mixed methods. The specific aims for the experimental analysis are to (1) determine the feasibility of the implementation of a CES treatment regimen in a population of military beneficiaries with RLS by monitoring levels of interest in the study, recruitment time, attrition rates, and adherence to the study protocol; and (2) gather preliminary data using CES to compare differences in RLS symptom severity and quality of life in individuals randomized to one of three study groups: a usual care group, an inactive (sham) device group, or an active CES device group. Because the personal impact of living with RLS has not been explored fully in the published literature, a third aim is (3) to describe the experience of individuals coping with the chronic symptoms of RLS and the impact of this disorder on their quality of life. Measurements of RLS symptom severity and quality of life will be collected over a period of 8 weeks and group differences over time will be analyzed using mixed linear models. Qualitative interview data will be analyzed using descriptive phenomenological methods. Findings from this study will inform the design and implementation of a larger study to establish the effectiveness of CES on RLS symptoms. Qualitative findings will provide much needed information on the priorities for future research and clinical management based on patients' perspectives. The ultimate goal of the research is to identify and to evaluate the comparative effectiveness of non-pharmacological treatments for RLS symptom management.
Proper analysis of urinary stone composition is a cornerstone for diagnosis, targeted treatment and recurrence prevention of urolithiasis. The aim of this study was to determine the composition, frequency and distribution of mixed stones according to gender and age of patients. A total of 42,519 urinary stones from 30,311 men and 12,208 women submitted between January 2007 and December 2020 were studied. Most urinary calculi consisted of two components (50.9%), followed by stones of a single constituent (27.1%) and three-component stones (21.9%), while four-component stones were only rarely identified (0.1%). Among all stones, 49.8% consisted of whewellite (COM), weddellite (COD), and mixtures of COM and COD, 33.8% were pure carbonate apatite (CA) and mixtures of CA with COM and/or COD, while 7.6% were composed of uric acid anhydrous (UAA), uric acid dihydrate (UAD), and mixed UAA and UAD. The remaining 8.8% of calculi were rare single-component stones and rare mixtures of various constituents. The number of stone components was inversely associated with age (p < 0.001). The proportion of men decreased significantly with the number of stone constituents, from 3.01:1 for single-component stones to 1.0:1 for four-component urinary calculi (p < 0.001). The vast majority of urinary calculi consisted of two or more components in varying proportions. While age was inversely associated with the number of stone constituents, the proportion of women increased significantly from single-component to four-component urinary calculi. A significant proportion of mixed stones could present a challenge for diagnosis and targeted recurrence prevention.
The HIV epidemic in South Africa (SA) is among the highest in the world. SA has a large antiretroviral therapy (ART) program, but some individuals exhibit poor ART adherence, which increases the likelihood of developing drug resistance and failing the only available first and second line ART regimens in SA. ART nonadherence contributes to greater morbidity, mortality, and higher likelihood of sexual HIV transmission when virus is detectable. At the same time, alcohol and other drug use is prevalent among HIV-infected individuals in SA and associated with worse ART adherence, lower rates of viral suppression, and HIV transmission risk behavior. Yet, despite the impact of untreated substance use on poor HIV treatment outcomes and continued HIV transmission, there is little if any integration of substance use and HIV care services in SA, which creates a fragmented and incomplete system of care. This study had three phases, first being formative, qualitative work which led to a systematic treatment adaptation phase. This third phase, the clinical trial, is based on this formative work and other empirical support using behavioral interventions to improve ART adherence and reduce substance use in resource-limited settings, including SA. This study is a Type 1 hybrid effectiveness-implementation trial of a lay counselor-delivered behavioral intervention for adherence and substance use integrated into the HIV primary care setting in SA. To ensure that those who need this intervention most will receive it, participants will be patients with HIV who are struggling with adherence (as defined in the investigator's inclusion criteria) and who have an elevated substance use risk.
The present invention relates to a pharmaceutical combination of compositions for use in the treatment or prevention of a disease having cells bearing a target antigen as a vaccine and to a method for vaccination of a mammal, especially of a human for raising a cellular immune response directed against cells of the mammalian recipient, especially human recipient, which cells express a target antigen. The target antigen can e.g. be an autoantigen like a malignant antigen, i.e. a tumour-specific antigen. The pharmaceutical combination of compositions comprises a first composition and a second composition, wherein the second composition is for administration to recipient subsequent to the administration of the first composition, e.g. 2 to 10 days after the first composition. The pharmaceutical combination of compositions has the advantage of raising an effective antigen-specific T-cell response against cells bearing a target antigen that can be a malignant autoantigen, e.g. for raising an antigen-specific T-cell response against cells bearing a tumour-antigen. A further advantage is that the pharmaceutical combination of compositions can raise an antigen-specific T-cell response within a comparatively short time.
People with COPD who have higher exposure to indoor pollutants, including particulate matter (PM), second hand smoke (SHS), and nitrogen dioxide (NO2) have worse respiratory morbidity including a higher risk of exacerbations. These effects are not obscured by smoking habit. Unfortunately, despite the clear detrimental impact of poor air quality on respiratory outcomes, regardless of smoking status, to investigators' knowledge, there are no studied environmental interventions targeting indoor air quality to improve respiratory health of smokers, thus ignoring a potential target for harm reduction.

Investigators propose a randomized controlled intervention trial to test whether targeted reductions of multiple indoor pollutants (PM, SHS and NO2) in homes of smokers with COPD will improve respiratory outcomes. Investigators have chosen a potent, multimodal intervention in order to maximize the opportunity to prove that there is a health benefit to active smokers with COPD from indoor air pollution reduction. After a one-month run in period in which all participants will receive smoking cessation strategies including Motivational Interviewing (MI) and nicotine replacement therapy, participants unable to quit smoking (n=120) will have 1:1 randomization to receive either 1) multi-component environmental intervention (active "high-efficiency particulate air"(HEPA) air cleaners + MI intervention for SHS reduction) or 2) sham air cleaners. Referrals to community resources for additional support will also be provided. Investigators aim to determine whether a multi-component environmental intervention (targeting PM, SHS and NO2 reduction) will improve respiratory morbidity (i.e., symptoms, quality of life, lung function and exacerbation risk) (Specific Aim #1) and intermediate outcome measures (i.e., markers of airway and systemic inflammation and oxidative stress) (Specific Aim #2) in smokers with COPD. Investigators anticipate that results from this study will inform clinical practice guidelines and health care policies aimed at reducing COPD morbidity and may have broader implications for indoor environmental recommendations for smokers with chronic disease.
The patients undergo repeated endoscopic cyanoacrylate injection every 3-4 weeks until obturation of gastric varices. Oral carvedilol is administrated during the whole study period, starting at 6.25 mg daily and increased until the maximum tolerated dose.
OBJECTIVE: Sleep duration is an important factor influencing health outcomes. The association between sleep duration and kidney function remains elusive. This study aimed to explore the association between sleep duration and chronic kidney disease (CKD) amongst Chinese adults.
METHODS: We conducted a cross-sectional study based on the China Health and Nutrition Survey (CHNS) in the wave of 2009. Participants were divided into three groups: ≤ 6 h/day (short sleepers), 7-8 h/day (regular sleepers) and ≥ 9 h/day (long sleepers) according to self-reported sleep duration. CKD was defined as estimated glomerular filtration rate < 60 mL/min/1.73 m2.
RESULTS: A total of 8096 Chinese adults (45.9% men) with a mean age of 50.6 years were included in the study. Compared with regular sleepers, both short and long regular sleepers had a higher prevalence of CKD. A U-shaped relationship between sleep duration and CKD was displayed by restricted cubic spline curve (P-overall < 0.001, P-nonlinear < 0.001). Multivariate logistic regression models revealed that both short and long sleep duration were clinically associated with higher odds of CKD, after adjustments for covariates [adjusted odds ratio (OR) 1.25 and 1.30; 95% confidence interval (CI) 1.00-1.56 and 1.08-1.54, for short and long sleep duration, respectively]. In subgroup analyses, we found the association was still observed in participants without hypertension or diabetes mellitus.
CONCLUSION: Short or long sleep duration was associated with CKD in the general population.
This research study is for patients with newly diagnosed Diffuse Large B-cell Lymphoma (DLBCL) of the activated B-cell (ABC) type who have not yet been treated. DLBCL is a cancer of a type of blood cell called B-lymphocytes. B lymphocytes are part of the body's immune system. There are different types of DLBCL. About a third of newly diagnosed DLBCL cancers are the ABC type. It has been observed that treatment does not work as well for patients with the ABC type compared to patients with other DLBCL types who receive standard treatment. However, at this time both ABC type and other DLBCL type patients receive the same standard treatments.

Patients with DLBCL who are otherwise healthy are usually treated first with the chemotherapy drug combination called R-CHOP. The drugs in this combination are "R" for rituximab, "C" for cyclophosphamide, "H" for doxorubicin which has a chemical name of hydroxydaunomycin, "O" for vincristine which has a trade name of oncovin, and "P" for prednisone. Depending on the local practice where you are treated, R-CHOP may be given for 6 or 8 cycles. A cycle could lasts for 14 or 21 days. The R-CHOP drug combination is approved for the treatment of DLBCL of all types, including ABC type. R-CHOP is standard care.

This study will test the standard R-CHOP21 against R-CHOP21 plus lenalidomide. The purpose is to see whether adding lenalidomide works better and is as safe as R-CHOP by itself. This study is only for patients with ABC type DLBCL who have not yet been treated. Lenalidomide is not approved for use in DLBCL. Its use in this disease is experimental. In this study, the experimental treatment is lenalidomide + R-CHOP21 x 6.

This study will use a gene expression profile (GEP) test to see if a patient has the ABC type. The results of this GEP test affect whether you may be treated on this study. Because the performance of this test has not been proven, it is for investigational use only, and is still under development. This means the GEP test is an experimental test.
The invention provides a Chinese medicine composition for treating acute and chronic granulocytic leukemia 1 and a preparation method thereof. 18 Chinese medicinal herbs including natural indigo, rehmannia root, isatis indigotica fort, turtle shell, papaya, Ningqi medlar, amur corktree bark, American ginseng, astragalus root, radix polygoni multiflori preparata and the like are compounded and prepared into oral capsules according to a proportion. The Chinese medicine composition is salty, sweet, pungent, amaroidal and cold and astrictive, has effects of clearing heat, detoxicating, tonifying Qi, nourishing blood, promoting appetite, relieving uneasiness, reducing a fever, strengthening body resistance to eliminate pathogenic factors, inhibiting growth of myelomonocytic granular cells and white blood cells, reversing sick cell functions to be normal, conditioning to balance a blood system, enhancing physical immunity, promoting neogenesis of red blood cells and hemoglobin and promoting rehabilitation, and has no toxic or side effects and a unique treatment effect on acute and chronic granulocytic leukemia. The Chinese medicine composition is orally taken three times a day with five pills each time by an adult after mixed with warm boiled water before meals; and for children, the dosage is slightly decreased according to the age or the quantitative dosage advised by a doctor. The Chinese medicine composition is taken for more than half a year until the international normal value of the blood system is reached and then taken for one month for consolidation preferably. During taking the Chinese medicine composition, following attentions are followed: patients are avoided eating sour, alkali, cholic, pickled, spiced, pungent, hot and high-protein foods; pregnant women are cautious to take the Chinese medicine composition; and the Chinese medicine composition is avoided being used together with Western synthetic hormone drugs.
INTRODUCTION: There is a substantial lack of data regarding the prevalence of irritable bowel syndrome (IBS) and functional dyspepsia (FD) in the region of Central/Eastern Europe. It is a well-described and known fact that environmental, ethnic, dietary, and cultural factors can influence the reporting of symptoms. Therefore, we aim to provide the first data documenting the prevalence of specific disorders of gut-brain interaction in Slovakia.
METHODS: This is a multicenter-based study. The study population consists of medical students from three medical faculties in Slovakia, mainly with Slovakian and Scandinavian permanent residency. Data collection was performed by means of anonymous questionnaires consisting of several demographic questions. Two forms of questionnaires were used. One was in paper form, and the second was distributed via email.
RESULTS: Altogether, 1061 students participated in this study. Symptoms of IBS were presented in 7.3% of students, and FD in 13%. In the Slovakian group, these were FD 12%, and IBS 7%. The subgroup from Scandinavia shows a prevalence of IBS of 11.7% and FD of 14.0%. A lack of exercise and a vegan diet are related to a higher presence of FD.
CONCLUSION: The results of this multicentre study represent the first published data for the presence of symptoms of IBS and FD in Slovakia. Our data also show a significantly higher prevalence of IBS in students from Scandinavia compared with those from Central/Eastern Europe. A higher frequency of physical exercise is associated with a lower presence of symptoms of FD. On the other hand, the symptoms of FD were mostly prevalent in the group adhering to a vegan and vegetarian type diet.
PURPOSE:To provide the titled drinking water, by boiling and concentrating sea- water, cooling the water, removing the precipitated salt, etc. by filtration, and diluting the remaining liquid with normal drinking water. CONSTITUTION:Sea-water is collected and concentrated by boiling. When salt is precipitated, the boiling-down of the sea-water is continued further, and the water is cooled and filtered with e.g. towel, etc. to remove the precipitated salt. The heating, cooling and filtration are repeated, and finally the water is cooled and centrifuged to collect the supernatant liquid. A large amounts of salt and magnesium sulfate are removed by this process. The residual liquid is diluted with conventional drinking water such as tap water to obtain the objective drinking water for habitual alcohol drinkers. A solution of pure NaCl is not sufficient for the purpose. Supply of the monitor components in sea-water to the habitual alcohol drinker is effective to remove the systemic malaise of the drinker.
The present invention discloses sea cucumber functional health-care products and a preparation method thereof. The sea cucumber functional health-care products are prepared from freeze-dried sea cucumber powder, taurine and vitamin E as main raw materials according to the recipe combining modern medicines and traditional Chinese medicinal theories. The freeze-dried sea cucumber powder can supplement kidney channels and benefit essence, is rich in proteins and amino acids which can promote the synthesis of immune substances, and can improve organism immune functions. The taurine and vitamin E also have the effects of improving immunity. The selected raw materials are wide in resources, reliable in quality, and affordable in prices. Besides, a large number of embodiment experimental studies show that the health-care products have good enhancing effects for body immune functions. Compared with other similar health-care food products, the health-care food products have certain comprehensive advantages.
BACKGROUND: The number of major operations performed in obese patients is expected to increase given the growing prevalence of obesity. Obesity is a risk factor for a range of postoperative complications including perioperative neurocognitive disorders. However, the mechanisms underlying this vulnerability are not well defined. We hypothesize that obese subjects are more vulnerable to general anaesthesia induced neurotoxicity due to reduced levels of adiponectin. This hypothesis was tested using a murine surgical model in obese and adiponectin knockout mice exposed to the volatile anaesthetic agent sevoflurane.
METHODS: Obese mice were bred by subjecting C57BL/6 mice to a high fat diet. Cognitive function, neuroinflammatory responses and neuronal degeneration were assessed in both obese and lean mice following exposure to 2 h of sevoflurane to confirm sevoflurane-induced neurotoxicity. Thereafter, to confirm the role of adiponectin deficiency in, adiponectin knockout mice were established and exposed to the sevoflurane. Finally, the neuroprotective effects of adiponectin receptor agonist (AdipoRon) were examined.
RESULTS: Sevoflurane triggered significant cognitive dysfunction, neuroinflammatory responses and neuronal degeneration in the obese mice while no significant impact was observed in the lean mice. Similar cognitive dysfunction and neuronal degeneration were also observed in the adiponectin knockout mice after sevoflurane exposure. Administration of AdipoRon partially prevented the deleterious effects of sevoflurane in both obese and adiponectin knockout mice.
CONCLUSIONS: Our findings demonstrate that obese mice are more susceptible to sevoflurane-induced neurotoxicity and cognitive impairment in which adiponectin deficiency is one of the underlying mechanisms. Treatment with adiponectin receptor agonist ameliorates this vulnerability. These findings may have therapeutic implications in reducing the incidence of anaesthesia related neurotoxicity in obese subjects.